WAM
VNDA icon

Wealthspire Advisors (Maryland)’s Vanda Pharmaceuticals VNDA Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-320
Closed -$6K – 1994
2019
Q1 		$6K Buy
320
+162
+103% +$3.69K ﹤0.01% 1778
2018
Q4 		$4K Buy
+158
New +$3.71K ﹤0.01% 1874

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s VNDA Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Vanda Pharmaceuticals (VNDA) in Q2 2019, closing a stake of 320 shares — an estimated $6K sold.

Wealthspire Advisors (Maryland) first reported a position in VNDA in Q4 2018 and held it in 2 quarters. The position peaked at $6K in Q1 2019. 164 funds tracked by Wall St. Rank hold VNDA as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Vanda Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 320 Vanda Pharmaceuticals shares in Q2 2019, an estimated $6K.
  • Wealthspire Advisors (Maryland) first reported a position in Vanda Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Wealthspire Advisors (Maryland)'s Vanda Pharmaceuticals position peaked at $6K in Q1 2019.
  • 164 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.